236 results on '"Dunlop, Adrian J."'
Search Results
2. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
3. Pilot study with randomised control of dual site theta burst transcranial magnetic stimulation (TMS) for methamphetamine use disorder: a protocol for the TARTAN study
4. Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study
5. Using mixed methods to establish tobacco treatment acceptability from the perspective of clients and clinicians of antenatal substance use services
6. The uptake of long‐acting depot buprenorphine for treating opioid dependence in Australia, 2019–2022: longitudinal sales data analysis
7. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia
8. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
9. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
10. Tobacco treatment incorporating contingency management, nicotine replacement therapy, and behavioral counseling for pregnant women who use substances: a feasibility trial
11. Escalating patterns of emergency health care prior to first admission with amphetamine psychosis: A window of opportunity?
12. Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial
13. Changes in Australian Early-Career General Practitioners’ Benzodiazepine Prescribing: a Longitudinal Analysis
14. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study
15. Antenatal care for alcohol consumption during pregnancy: pregnant women’s reported receipt of care and associated characteristics
16. Substance use, socio‐demographic characteristics, and self‐rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study.
17. Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs
18. Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019
19. Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal
20. Changes in cigarette and alcohol use during cannabis abstinence
21. A practice change intervention to improve antenatal care addressing alcohol consumption by women during pregnancy: research protocol for a randomised stepped-wedge cluster trial
22. Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study
23. QT interval prolongation in opioid agonist treatment: analysis of continuous 12‐lead electrocardiogram recordings
24. The pattern of anxiolytic and hypnotic management by Australian general practice trainees
25. The prevalence of QT prolongation in a population of patients with substance use disorders
26. Does brief chronic pain management education change opioid prescribing rates? A pragmatic trial in Australian early-career general practitioners
27. Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia
28. Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019.
29. E‐cigarette or vaping product use‐associated lung injury in an adolescent
30. Additional file 1 of Using mixed methods to establish tobacco treatment acceptability from the perspective of clients and clinicians of antenatal substance use services
31. Additional file 4 of Using mixed methods to establish tobacco treatment acceptability from the perspective of clients and clinicians of antenatal substance use services
32. Additional file 2 of Using mixed methods to establish tobacco treatment acceptability from the perspective of clients and clinicians of antenatal substance use services
33. Additional file 3 of Using mixed methods to establish tobacco treatment acceptability from the perspective of clients and clinicians of antenatal substance use services
34. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study
35. Smoking cessation interventions for pregnant women attending treatment for substance use disorders: A systematic review
36. Opioid prescribing in Australia: too much and not enough
37. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
38. Predictors of alcohol use during pregnancy in Australian women
39. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine
40. Additional file 1 of The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
41. Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
42. Alcohol and other drug health‐care providers and their client's perceptions of e‐cigarette use, safety and harm reduction
43. PHARMACEUTICAL OPIOID TREATMENT PRESENTATIONS PRESCRIBED METHADONE OR BUPRENORPHINE IN THREE NEW SOUTH WALES LOCAL HEALTH DISTRICT DRUG TREATMENT SERVICES: Paper 111
44. ADDRESSING PSYCHOSTIMULANT USE PROBLEMS IN NSW, AUSTRALIA: ALCOHOL AND DRUG SERVICE TRAINING NEEDS: Paper 202
45. USE OF BIRDʼS NEST DRAWING IN ASSESSING ATTACHMENT IN FAMILIES WITH SUBSTANCE USE PROBLEMS: Paper 234
46. KRONIC IN THE CLINIC: A NEWCASTLE PERSPECTIVE: Paper 227
47. THE IMPACT OF SATIVEX® ON COGNITIVE FUNCTION DURING TREATMENT FOR CANNABIS WITHDRAWAL: Paper 109
48. A RANDOMISED CONTROLLED TRIAL OF SATIVEX® AS AN AGONIST REPLACEMENT THERAPY DURING CANNABIS WITHDRAWAL: Paper 153
49. WORKSHOP: THE IMPACT OF PARENTAL SUBSTANCE USE ON CHILDREN. A DISCUSSION ABOUT CHILD PROTECTION AND TARGETED INTERVENTION: Paper 270
50. PRESENTATION 2 – OUTCOME MATRIX – DEVELOPING A COMPOSITE MEASURE FROM THE ATOP BUT WHAT ABOUT COMPLEXITY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.